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A number of hereditary diseases are amenable to treat-
ment by manipulation of the environment, and the results
of this approach are encouraging. Some of these condi-
tions need to be diagnosed soon after birth if serious
effects are to be prevented. Neonatal screening pro-
grammes are therefore indicated. Other hereditary dis-
eases either defy treatment completely or else have an
extremely bad prognosis even when the best treatment is
provided. Recent advances in the field of prenatal diag-
nosis of hereditary disorders have made it possible to
'prevent' the birth of children with a number of these
conditions.
5. Afr. Med. l., 48. 1500 (1974).
Hereditary diseases are assuming greater relative
importance in the practice of medicine. In the developed
countries 25 - 30 0 0 of admissions to paediatric hospitals
are for diseases due. wholly or in part, to genetic causes.
In our cQuntry we are confronted with problems of
malnutrition and infectious disease of such magnitude
that it might be considered a 'luxury' or a complete lack
of sense of priority to concern oneself with hereditary
disease. Nevertheless, we do have sections of our popu-
lation (not confined to the Whites) in which malnutrition
and infectious diseases are no longer serious problems.
These 'sophisticated' South Africans are increasing in
number annually. It is reasonable to expect that if people
respond to appeals to restrict the size of their families
they must be helped to ensure that the children they do
produce will be healthy-in body and mind.
Until about 3 years ago the medical geneticist could
help diagnose hereditary diseases and treat a few of them;
but, for all practical purposes, his main function was the
giving of probability figures relating to the risks of
recurrence. Then some major break-throughs were made
which enabled certain genetic diseases (both chromosomal
and biochemical) to be diagnosed when the fetus was
sufficiently small to permit consideration of termination
of pregnancy. Commensurate with these advances in
antenatal diagnosis came changes in society's attitude to
abortion.
The physician. dealing with families in which there was
a high risk of genetic disease, was no longer a relatively
helpless bystander but became an important dramatis
personae, capable of 'preventing' the birth of children
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with severe crippling, incapacitating diseases, many of
which are fatal within a few years of birth.
In September 1973 I attended the Fourth International
Conference on Birth Defects held in Vienna.
The National Foundation-March of Dimes, sponsors
of this Conference, is a remarkable voluntary health
organisation. Founded in 1938 by President Roosevelt
to fight poliomyelitis it had, within 20 years, helped con-
quer the disease. In 1958 the Foundation turned its
attention to birth defects. A broad definition of the term
birth defects was adopted: 'Those human conditions,
significantly handicapping to their bearers, that are of
prenatal origin due to genetic, environmental, or combined
genetic-environmental causes, and manifest at birth or
various ages later in life'.
There was a strong muJtidisciplinary flavour to the
Conference, with molecular biologists and other labora-
tory scientists interacting with obstetricians, paediatricians
and human geneticists of different subspecialities. There
were teratologists, epidemiologists. virologists, social
workers, veterinarians and pharmacologists. Two hundred
and eighty-nine papers were read in 5 plenary sessions.
at 9 workshops and at 14 sessions for free communi-
cations, many of which were held simultaneously.
This article concentrates on one general theme, namely
the prevention of hereditary disease, related to problems in
medical genetics as they present themselves in South
Africa.
Replacing the abnormal gene with a normal gene
would appear to be the ultimate in gene therapy and
the exciting feats of synthesising DNA were reviewed by
Dr Paul Marks of Columbia University, New York City,
in whose laboratory attempts to introduce globin genes
into animal cells in viTro have met with some success,
Merril, from the National Institute of Health, Bethesda,
Maryland, who claimed a year ago to have succeeded in
introducing a gene from one cell into another by means
of a virus (the prokaryotic galactose operon genes.
carried by an Escherichia coli tranducing lambda phage,
into human galactosaemic fibroblasts) presented. new data
which tended to confirm his earlier work.
But genetic engineering has not 'arrived': it is still in
the realm of science fiction. An alternative approach to the
treatment of genetic disease is environmental engineering
or manipulation by substrate restriction or metabolite
(product) replacement, thereby bypassing the mutant gene
product. Dr C. R. Scriver of McGill University Montreal
Children's Hospital reviewed this field.
Table I sets out some of the hereditary diseases which
are susceptible to treatment by dietary or pharmacological
means. It will be seen that by substrate reduction, by
cofactor supplementation. by metabolite or enzyme re-
placement. or by removal of toxic products many of the
sequelae of these genetic diseases may be prevented.
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TABLE I. HEREDITARY (METABOLIC) DISEASES
SUSCEPTIBLE TO TREATMENT (DIETARY OR
PHARMACOLOGICAL)*
• Material adapted from Scriver.2•3 and O'Brien and Goodman.<
Abbreviations: S = substrate restriction; P = product replacement;
Enz = enzyme replacement; V = vitamin supplementation; term follow-
ing indicates component adjusted.
Another group of inherited disorders place the patient
at an altered risk in particular environments (Table II).
The environment in question is often that produced by
the medical practitioner in his well-intentioned attempt
to help the patient. Isoniazid in the usual dosage can
cause polyneuritis due to a deficiency of a transacetylase
enzyme which, when present, will conjugate the drug.
We are at the moment engaged in a study to determine
the prevalence of this trait in Southern Africa and can
report that the Kalahari San ('Bushmen') have a much
lower prevalence of the deficiency than all other groups
so far tested." Anaesthetists occasionally are made aware
of the dangers of genetic traits like pseudo-cholinesterase
Disease
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variation when a patient fails to breathe for many hours
after receiving a 'normal' dose of succinylcholine.
But the doctor cannot be blamed for all the catastrophes
in this category-self-inflicted noxious agents like alcohol
and tobacco smoke can, if the individual has a particular
inherited trait, be responsible for alcoholism or pulmonary
emphysema. In both of these categories individuals can
be identified by mass screening procedures and steps
taken to prevent the development of the disease by the
appropriate means.
If treatment, in order to be successful, has to be
instituted within a matter of days after birth, as with
classical phenylketonuria (PKU), then neonatal screening
is essential. I understand from Or Sylvia Johnson of the
Johannesburg City Health Department that her Depart-
ment between 1964 and 1969 tested approximately 43000
White, 5 000 Coloured and 750 Asian babies aged 2 - 3
weeks with the Phenistix test on urine without finding a
single case of phenylketonuria. Holtzman of the Johns
Hopkins Hospital, using the urine ferric cWoride test,
found that as many as 45% of PKU infants were
initially negative. Since 1963, screening for blood phenyl-
alanine elevations has been adopted and an evaluation
of the success of the programme was attempted. It was
found that 70% of newborns were screened before an
elevated phenylalanine level could be expected to be
detected. At least 22 infants (8% of infants with PKU
screened) were missed by neonatal screening. Differences
in interpretation and performance of the test wer-e probably
responsible for the differences in the incidence of PKU.
Follow-up of suspected cases of PKU was poor,
24,9 days being the mean period taken for a repeat test
to be carried out.
Neonatal screening programmes are beset by many
problems. A number of countries have introduced them
and the experience of the Quebec network is most
encouraging. Using a fiuorometric assay and a sample
of blood submitted through the post on a piece of filter
paper they claim good results screening for phenylketo-
nuria, tyrosinaemia and galactosaemia. One-dimensional
partition chromatography of amino acids in the urine of
the newborn infant is also carried out-a separate sheet
of filter paper being used for the collection. They are
subsidised by the Government-$3 per birth, which
covers the costs of these tests and supervision of the
treatment of cases discovered. In addition, they have been
able to add other investigations, like that for a Tay-Sachs
disease carrier screening programme, at a marginal
increase in cost.
The time has come to reconsider neonatal screening
for inborn errors of metabolism in South Africa.
Other inherited metabolic defects need not be detected
in the neonatal period for catastrophic results to be avoided.
There is probably time enough to test a person for his
acetylator status before putting him on isoniazid therapy;
or his plasma pseudocholinesterase type before giving
him an anaesthetic which includes succinylcholine (Scoline).
But in certain populations it may be wise to screen all
patients admitted to hospital so that the physician or
anaesthetist is alerted to the dangers of administering
certain drugs. Glucose-6-phosphate dehydrogenase defi-
1502 S.-A. MEDIESE TYDSKRlF 20 Julie 1974
TABLE 11. SOME INHERITED DISORDERS PLACING THE PATIENT AT ALTERED RiSK IN PARTICULAR ENVIFlONMENTS·
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ciency would make the physician cautious when adminis-
tering oxidant drugs like aspirin, phenacetin, sulpho-
namides or primaquine; in South Arica, as we are all
aware, it would be dangerous to give barbiturates or
sulphonamides to someone with porphyria variegata. In
fac~ 20 years ago Dr Geoffrey Dean screened all patients
for this condition prior to their admission to hospital in
Port Elizabeth-this might well have been something of
A pioneering venture.
So far we have considered herditary diseases amen-
able to treatment and the results are reasonably encourag-
ing. Although we are not tackling the problem of preven-
tion at the gene level, by controlling the environment
individuals are helped to live fairly normal, useful lives.
There are unfortunately a number of hereditary diseases
which either defy treatment completely or els~ have an
extremely bad prognosis even when the test treatment
is provided. It is for the 'prevention' of diseases such
as these that antenatal diagnosis and selecLve abortion
may be offered. In order to illustrate the way in which
such programmes operate or could conceivably operate,
a recessively inherited disease (Tay-Sachs disease), a
chromosomal aberration (Down's syndrome, trisomy-21
or 'mongo'ism') and a multifactcr:ally inherited disea~e
(spina bifida/anecephaly) will be discussed.
TAY·SACHS OISEASE
Tay-Sachs disease, one of the lipidoses, is characterised
by an accumulation of monosialoceramidetrihexosicle
(G~,,) in the neurones of the brain, owing to the absence
of hexosaminidase A, which is essential for the initial step
in the degradation of ~.
An affected child appears normal at birth but by 4 - 6
months is listless and hypotonic with steadily increasing
retardation. The macula degenerates and 90% of cases
show a cherry-red spot at the fovea. As cerebral degene-
ration proceeds the EE G becomes abnormal and epileptic
seizures often occur before death supervenes between
2 and 4 years of age_
At autopsy the brain contains up to 100 times the
normal amount of G"" and the spleen and liver also
contain detectable amounts of G"2. Hexosatninidase A
is not detectable in the serum or white ceIls.
The parents can be shown to be carriers of the gene for
Tay-Sachs disea~e by possessing reduced levels of hexo-
saminidase A in serum and white cells. 'the disease is
inherited as an autosomal recessive and the affected fetus
can be diagnosed as early as 9 weeks' gestation. Amnio-
centesis at 14 - 16 weeks' gestation and assay of hexos-
aminidase A in the amniotic fluid, but preferably in
cu:tured amniotic cells, can ~how conclusively if the fetus
is suffering from the disease.
It has b~en known for over 70 years that Tay-Sachs
disease is COmmoner in the Ashkenazi Jewish populations
originating in certain regions of easten Europe than
in other populations and it is likely that as many
as 1 in 25 to I in 30 Ashkenazi living in the USA carry
this defective gene. Preliminary data show tbat in South
Africa there is a similar prevalence and a fhass screening
programme could be expected to reveal all carriers.
With the exception of the few recessively inherited
diseases where prospective parents have been screened
for the presence of the gene, parents are not usually aware
that they are carriers of the recessive trait until a child
with the disease has been born. It is apparent, therefore,
that the birth of the first affected child cannot be
-
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TABLE Ill. PREVENTION OF AUTOSOMAL RECESSIVE DISEASES: RETROSPECTIVE DIAGNOSIS AFTER BIRTH OF
AFFECTED CHILD*
Total Number of
number Number Number Number of abortions
of of normal of affected intra-uterine of affected
Pregnancy fetuses children children diagnoses fetuses
1 480 360 120
2 360 270 90
3 120 90 120 30
210 157 210 53
4 75 56 75 19
5 25 18 25 6
6 7,6 5,7 7,6 0,9
7 2,3 1,6 2,3 0,67
8 0,6 0,48 0,6 0,17
Total 1280,5 959,78 210 440,5 109,74
• Corrected version of Motulsky et al. 7 480 matings between heterozygote carriers; reproductive aim is normal children per couple.
prevented. But if intra-uterine diagnosis of tbe particular
disease is possible the birth of subsequently affected
children can be prevented.
Let us consider the quantitative problems involved in
any programme designed to help such carrier couples have
2 normal children. To facilitate the calculations 480
matings are considered and the various steps are shown
in Table Ill.
After the first pregnancy 360 couples will have 1
unaffected child each, while 120 will eacb have bad an
affected child and will have been alerted. The 360
couples will embark upon their second pregnancy un-
aware of their carrier status and 25 0 0, i.e. 90 couples will
produce an affected child. For them, and the 120 couples
already alerted antenatal diagnosis with selective abortion
is offered in future pregnancies. Thirty of the latter
group (i.e. 25 00 of 120) will be found on antenatal testing
to be carrying an affected fetus while 90 will be reassured.
Embarking on a third pregnancy will be 210 couples-
the other 270 having completed their families of 2
unaffected childem without ever knowing that they were
carriers of the gene.
Intra-uterine diagnosis will have to be attempted in
210 couples - 53 will need an abortion and 157 will have
been reassured that they have an unaffected child and
will therefore have completed their families. The 75 un-
fortunates will have an amniocentesis during their fourth
pregnancy - 56 will be reassured while 25 will have to
embark on a fifth pregnancy. Fewer than 8 couples will
need to undertake a sixth pregnancy and less than I couple
out of the 480 will be unable to have fulfilled the aim of
having 2 unaffected children after 8 pregnancies.
A total of 440 intra-uterine diagnostic procedures and
110 abortions would have been required for each of the
480 couples to have 2 normal children. But 210 affected
children will also have been born and this is only 30
fewer than the affected number, assuming that the 480
couples had had 2 children each irrespective of the
outcome of the pregnancy. The net reduction in affected
children would be from 240 to 210 or only 12,5°0.
But perhaps a fairer comparison would be between
the number of affected children produced in monitored
pregnancies as calculated above, and the number of
affected children produced by 480 heterozygous parents
if they were to reproduce until each couple had 2 normal
children without monitoring of pregnancies subsequent
to the birth of an affected child. Here the reduction is
from 320 affected offspring to 210, or a 34°0 reduction.
Some words of caution need to be added at this point.
Firstly, there are still relatively few genetic diseases in
which the biochemical lesion has been sufficiently well
characterised to permit of antenatal diagnosis. Secondly,
many recessively inherited diseases are not diagnosed
early enough to enable the rational approach of prenatal
diagnosis to be planned prior to the second (or even the
third) pregnancy.
Nevertheless, the type of programme outlined above
could be instituted for a number of diseases with, under
ideal conditions, the results predicted.
The detection of all heterozygotes prior to marriage
and reproduction and the successful implementation of
an antenatal diagnostic programme could, theoretically,
result in the prevention of the birth of all children
suffering from a recessively inherited disease. It is not
at this stage practicable to screen everyone for a parti-
cular mutant gene but certain 'high-risk populations'
(high frequencies of the gene) can be defined and these
offered screening tests for detecting carriers.
The Ashkenazi Jewish population of South Africa with
its high prevalence of Tay-Sachs disease would qualify
for consideration as a high-risk population. Making a
number of assumptions we have calculated that about 1
child with Tay-Sachs disease will be born to Ashkenazi
parents in South Africa per year and that at anyone
time there will be about 4 such affected children in the
country (Table lV). In order to prevent, by selective
abortion, the birth of this child it is calculated that about
20000 people will have to be tested initially. and perhaps
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500 every subsequent year. while 4 amniocenteses per
annum will have to be performed.
TABLE IV. TAY-SACHS DISEASE IN THE SOUTH AFRICAN
ASHKENAZI JEWISH POPULATIONS: SOME THEORETICAL
CONSIDERATIONS
Ashkenazi Jewish population
Approximate frequency of Tay-Sachs
carrier state
Estimated number of couples of child-
bearing age
Frequency of marriage between car-
riers (1 in 30)2 ...
estimated number of marriages
between carriers 19 500
900
Assumed maximum mean number of
children per sibship ..
Probability that a child of a carrier
couple will have TSD
Assumed mean duration of child-
bearing period ...
.'. annual mean No. of births of TSD













6. Definition of benefits-an educational programme
lasting months or even years must precede the screening
so that people are made aware of the benefits of such
an investigation.
7. Counselling needs-when the results of tests have been
communicated to subjects there must be sufficient trained
personnel to undertake counselling.
8. Carrier stigmatisation can only be avoided by skilful
education before the testing is done and skilful counsel,
ling afterwards.
9. Responsibility to other family members-it is hoped
that when a carrier has been detected he will feel a
sense of responsibility for other family members and
encourage them to be tested.
10. Need for psychosocial evaluation and follow-up-
with any new venture careful evaluation and folIow-up
are essential. No individual likes to be told he is 'different'
and screening programmes must be modified in the light
of the findings.
11. Medical and biological significance of heterozygosity
-arguments stilI rage over the significance of the high
Tay-Sachs carrier rate in the Ashkenazi Jews. If it is due
to founder effect (one type of random genetic drift) then
the gene in the heterozygous state probably has no
biological or health significance but if the high rate is
due to heterozygote advantage-and there are preliminary
data suggesting an advantage conferred against tuberculo-
sis-then attempts must be made to define what this
advantage may be.
There are II points to consider when discussing a
Tay-Sachs screening programme, according to Dc Michael
Kaback:
I. Legislation-the programme should be entirely
voluntary.
2. Role of the community-the impetus for the programme
and the organisation must come from the community,
mainly from religious and social groups.
3. Informed consent-individuals requesting investigations
must have a clear understanding of what it is alI about.
4. Coercion and the right not to know-the wishes of
certain individuals not to know their carrier status must
be respected.
5. Protection of privacy-results of all investigations must
be treated as confidential and not be divulged without
the subject's consent.
DOWN'S SYNDROME
TABLE V. RISK OF DOWN'S SYNDROME ACCORDING TO
MATERNAL AGE'
It is unnecessary to describe the clinical features of this
condition, commonly called mongolism, and now known
to be due to a complement of three No. 21 chromosomes
instead of the usual two. Approximately 98 0 0 of cases
are due to a non-disjunction while the remaining 2%
are due to an unbalanced translocation state. The former
are sporadic, with a marked maternal age effect being
apparent, and about half the latter are sporadic, too.
About half of the translocation type are familial, with
one parent a balanced translocation carrier. It is manda-
tory to detect these carriers if sound counselIing is to be


























Maximum duration of life of a TSD
sufferer
... maximum mean number of Ash-
kenazi children suffering from TSD
in RSA at anyone time ...
Maximum estimate of number of
Jewish children aged 0 - 4,5 years
in RSA
95% confidence limits of estimated
number of TSD sufferers ...
.'. there is only a probability of 5~o or
less that at anyone time there are
more than 8 Ashkenazi sufferers
from TSD in the country
·~
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of future children with Down's syndrome achieved.
Table V shows the strong maternal age effect in the
production of non-disjunction cases, and it is apparent
that certain age groups constitute 'high-risk' populations.
Or Sylvia Johnson of Johannesburg very kindly compiled
data on the number of White, Asiatic and Coloured
women in South Africa of the various age groups who
had babies during 1970 (Table VI). It can be seen that
whereas only 2,22~0 of White women have babies when
they are 40 years or older, the corresponding proportions
for Asians and Coloureds are 3,8'}0 and 5'%, respectively.
Presumably the proportion is even higher among our
negroid population.
Down's syndrome can be diagnosed with certainty in
a 14 - 16-week fetus by karyotyping of cells obtained
by amniocentesis. It is, therefore, theoretically possible to
diagnose all such cases, and selective abortion of such
fetuses could eliminate the condition. At the present stage
et technology such a programme is out of the question,
but in many centres it may already be feasible to offer
such a service to older mothers.
We have made a few calculations based on the number
of births for 1970 to Whites, Asiatics and Coloureds in
South Africa and the results are presented in Table VII.
(If the remainder of the population were to be included
the figures would have to be multiplied by 3 to give
approximate estimates.) If phase I were directed at a
target population of women aged 45 years or older, and
if there were a 90~0 acceptance, then 921 amniocenteses
will have to be carried out to diagnose the 22 expected
cases of Down's syndrome. If these fetuses were aborted
then 8"0 of the cases of Down's syndrome will have
been prevented. A 50~0 acceptance of the service would
result in 12 cases being diagnosed and a 4~~ prevention
rate.
H facilities were available and phase 11 of the preven-
tive programme could be introduced-with a 90'}0 accep-
tance-21 "u of cases of Down's syndrome would be
prevented (Table VII). When extended to 35-year-olds
and over, 36% of cases could be prevented, but this would
require nearly 20000 amniocenteses per year-an impossi-
bly huge task with our limited resources.
SPINA BIFIDA AND ANENCEPHALY
M uItifactorialiy inherited disorders are more common
than Mendelian or chromosomal disorders and, among
the former. abnormalities of the neural tube are probably
the commonest: 7 - 8/ I 000 total births in Ulster and
Wales, 4/1000 in South-East England, 2 - 3/1 000 over
most of Europe, and less than 2(1 000 in West African
and eastern Asian populations.





Total births 35 - 39 yrs 40 - 44 yrs 45 - 49 yrs
88886 5479 1518 161
(6%) (2%) (0,2/0)
21082 1809 676 136
(8,6/0) (3%) (0,6/0)
74429 7451 2986 596
(10/0) (4%) (0,8%)
TABLE VII. PREVENTIVE PROGRAMME FOR DOWN'S SYNDROME IN SOUTH AFRICA











































• Whites. Asiatics and Coloureds only.
1506 S.-A. MEDIESE TYDSKRIF 20 Julie 1974
Empiric risk figures for recurrence after the birth of 1
or 2 children with spina bifida/anencephaly are not
available for our population, so we have to counsel
patients using figures obtained in other countries. After 1
affected child the recurrence risk is 1 in 20, after 2
affected children, 1 in 10.
A workshop at Vienna was devoted to the management
of spina bifida/anencephaly, and a number of clinicians
dealt with the subject of contra-indications to active
therapy. In Table VID are summarised Lorber's contra-
indications, which include gross paralysis of the legs,
extending up into the thoracic region and the presence
of hydrocephalus or other gross congenital defects, if
present at birth. Even if closure of the defect has been
achieved, the subsequent development in the newborn
period of meningitis or ventriculitis, in the presence of
serious neurological handicap and hydrocephalus, would
constitute contra-indications to active therapy. Some work-
ers referred to this approach as the 'judicious management'
of the patient.
TABLE VIII. . CONTRA-INDICATIONS TO ACTIVE THERAPY
OF MYELOMENINGOCELE
At birth
Gross paralysis of the legs
Thoracolumbar or thoracolumbosacral lesions
Kyphosis or scoliosis
Grossly enlarged head (2 cm or more > 90th percentile)
Intracerebral birth injury
Other gross congenital defects (e.g. cyanotic heart
disease, ectopia of bladder)
After closure, in newborn period
Meningitis or ventriculitis when there is serious neuro-
logical handicap and hydrocephalus
Later
In any life-threatening episode in a child who is severely
handicapped by gross mental and neurological defects
Lorber, Sheffield
Renwick's 'blighted potato' hypothesis as a factor in
the causation of spina bifida/anencephaly did not receive
any attention. Methods for detecting neural tube mal-
formations in lItero, thereby enabling selective abortions
to be carried out, include: .
Fetoscopy. The technique was reviewed and although
spectacular successes were not reported, it would seem
as though within the next few years, instrumentation may
improve to a sufficient extent to permit its use for detecting
abnormalities before 20 weeks' gestation.
Ultrasound detection of anencephaly at 17 weeks' gesta-
tion has been made, and Campbell of Queen Charlotte's
Hospital, London, reported some conspicuous successes
obtained with this technique. He said that 50% of
women attending their antenatal clinic were now subjected
to the examination.
Alpba-fetoprotein. A significant advance in the diag-
nosis of neural tube abnormalities was repol'ted about a
year ago when David Brock, working in Edinburgh,
observed a raised level of a-fetoprotein in the amniotic
fluid of fetuses subsequently born with spina bifida.
Dr Ferguson Smith reported the first two successful
prospective diagnoses.
Brock et al.' reported an anencephalic pregnancy first
diagnosed by measurement of a-fetoprotein in maternal
serum at 16 weeks' gestation. There are obvious difficulties
in introducing this sort of screening test (levels are raised
in many conditions unrelated to pregnancy, and in
threatened abortion, non-specific cases of fetal distress
and intra-uterine death) but if a raised maternal' serum
level of a-fetoprotein were simply employed to detect
these patients needing amniocentesis and the measurement
of a-fetoprotein levels in amniotic fluid, then a great
advance----in the detecfon of this tragic disease will have
been made.
CONCLUSION
It is impossible in the space available to give a com-
prehensive account of the Fourth International Conference
on Birth Defects and I have instead concentrated on one
theme-the prevention of hereditary diseases.
The questions considered affect each one of us, if we
take our responsibilities to society at all seriously. Moral
and ethical issues are raised by almost every 'preventive'
measure discussed. The 'judicious management' of children
with meningomyelocele is a euphemism for killing the
child with a bad prognosis; amniocentesis and selective
abortion a euphemism for killing the fetus with a
genetic disease. Concerned people-geneticists, paediatri-
cians, and obstetricians, as well as theologians, philoso-
phers and lawyers, need to b::: convened in South Africa
to discuss these problems, if we are not to be left behind.
A few months ago the Southern African Inherited
Disorders Association was formed. This is a lay/medical
organisation, one of whose aims is the education of the
public in the field of inherited diseases and it is suggested
that a discussion of the moral issues in medical genetics
should be one matter to which it might draw public
attention.
Medical genetics has come a long way in a relatively
short time. Even though there are many problems still
awaiting solution it can be claimed that during the past
3 years or so some 'giant steps' have been taken and the
way is now clear to deal effectively with a significant
number of hereditary diseases.
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